BEST UNLIMITED TURBO LONG CERTIFICATE - ASTRAZENECA | Market Closed - Borsa Italiana 01:34:59 21/05/2024 am IST | ||
| 2.975 EUR | 0.00% |
|
| Current month | +0.51% | ||
| 1 month | +64.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 20/24/20 | 2.975 | -1.82% |
| 17/24/17 | 3.03 | -1.62% |
| 16/24/16 | 3.08 | -0.65% |
| 15/24/15 | 3.1 | -4.91% |
| 14/24/14 | 3.26 | +0.31% |
Real-time Borsa Italiana
Last update May 21, 2024 at 01:34 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| S34727 | |
| ISIN | DE000SW77CR9 |
| Date issued | 27/03/2024 |
| Strike | 9,563 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.41 € |
|---|---|
| Lowest since issue | 1.202 € |
| Spread | 0.13 € |
| Spread % | 4.26% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
167.9
USD
Spread / Average Target
+9.24%
- Stock Market
- Certificates
- S34727 Certificat